"A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors"

"Trattamento con Fattore VIIA Ricombinante (rFVIIA) ad alte dosi in emofilici con inibitore: Studio randomizzato crossover."

Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders

AbstractData from the Italian Hemophilia Centres were collected to perform a retrospective survey of joint arthroplasty in patients with severe hemophilia. Twenty-nine of 49 hemophilia centers reported that 328 of the 347 operations were carried out in 253 patients with severe hemophilia A (HA) and 19 in 15 patients with severe hemophilia B (HB). When results were normalized to the whole Italian hemophilia population (1770 severe HA and 319 severe HB), patients with HA had a 3-fold higher risk of undergoing joint arthroplasty (odds ratio [OR], 3.38; 95% confidence interval [CI], 1.97-5.77; P < .001). These results were confirmed after adjustment for age, HIV, hepatitis C virus (HCV), and…

"Prophylaxis with Factor VIII Protects Children with Hemophilia a from inhibitor Development."

"A randomized crossover study of high- and standard-dose recombinant factor VIIa for home treatment of hemarthroses in hemophiliacs with inhibitors."

Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis

Immune Tolerance Induction (ITI) in patients wuth hemophilia A and inhibitors: the Italian Retrospective-Prospective Registry - the PROFIT Study .